Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Drug Safety
Published in: Drug Safety 10/2011

01-10-2011 | Editorial

Off-Label Pharmacovigilance

Author: Professor I. Ralph Edwards

Published in: Drug Safety | Issue 10/2011

Login to get access

Excerpt

This edition of Drug Safety contains the abstracts for the annual International Society of Pharmacovigilance (ISoP) meeting being held in Istanbul, Turkey, 26–28 October 2011.[1] Browsing the agenda for the meeting indicates that a session will be devoted to off-label use of drugs. This interesting topic has not been pursued much in pharmacovigilance, but it should be in the core of what we do. …
Literature
1.
Abstracts: 11th ISoP annual meeting “Next stop: Istanbul — bridging the continents!’, Istanbul, Turkey, 26–28 October 2011. Drug Safety 2011; 34 (10): 883–1026
2.
When off-label is off target [editorial]. Nat Med 2011; 17 (6): 633
3.
Levi M, Levy JH, Andersen HF, et al. Safety of recombinant activated factor VII in randomized clinical trials. N Engl J Med. 2010 Nov 4; 363(19): 1791–800PubMedCrossRef
4.
Mallarkey G, Brighton T, Thomson A, et al. An evaluation of eptacog alfa in nonhaemophiliac conditions. Drugs 2008; 68(12): 1665–89PubMedCrossRef
5.
van Grootheest AC, Edwards IR. Labelling and ‘Dear Doctor’ letters: are they noncommittal? Drug Saf 2002; 25(15): 1051–5PubMedCrossRef
6.
Preston FE, Edwards IR. Postpartum purpura fulminans: successful management with streptokinase. BMJ 1973 Aug 11; 3(5875): 329–30PubMedCrossRef
7.
Edwards IR. Malaria with disseminated intravascular coagulation and peripheral tissue necrosis successfully treated with streptokinase. BMJ 1980 May 24; 280(6226): 1252–3PubMedCrossRef
8.
Zenz W, Zoehrer B, Levin M, et al. Use of recombinant tissue plasminogen activator in children with meningococcal purpura fulminans: a retrospective study. Crit Care Med 2004 Aug; 32(8): 1777–80PubMedCrossRef
Metadata
Title
Off-Label Pharmacovigilance
Author
Professor I. Ralph Edwards
Publication date
01-10-2011
Publisher
Springer International Publishing
Published in
Drug Safety / Issue 10/2011
Print ISSN: 0114-5916
Electronic ISSN: 1179-1942
DOI
https://doi.org/10.2165/11596140-000000000-00000

Other articles of this Issue 10/2011

Drug Safety 10/2011 Go to the issue

Original Research Article

The Case-Population Study Design

Original Research Article

Drug-Induced Taste and Smell Alterations

Review Article

Drug-Induced Photosensitivity

Original Research Article

Effect of Pre-Medication on Early Adverse Reactions Following Antivenom Use in Snakebite

Short Communication

Fluoroquinolone-Associated Myasthenia Gravis Exacerbation

Meeting Report

Communication in Drug Safety